Skip to content

Study · Animal study (in vivo) · mouse · 2008

9 results

Exendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh islets.

Juang JH, Kuo CH, Wu CH, Juang C

Cell transplantation1 Jan 2008Cited by 18 (Europe PMC)

PMID18819252 (opens in a new tab)DOI10.3727/096368908786092766 (opens in a new tab)PepBankPUB-18819252
Source linkPubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice receiving islets, exendin‑4 lowered glucose versus controls from day 3, although glucose declined in both groups.

    In plain wordsIn mice, glucose fell in both groups but was lower with exendin‑4 than without it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose trajectory
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Blood glucose levels in both groups decreased progressively after transplantation, and the exendin-4-treated group had had lower blood glucose than controls since day 3.
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice receiving islets, exendin‑4 increased euglycemia achievement versus controls.

    In plain wordsIn mice, exendin‑4 increased normal glucose achievement compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseEuglycemia achievement
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    By 6 weeks, euglycemia was achieved more in mice treated with exendin-4 than in controls (100% vs. 62.5%, p = 0.018).
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice receiving islets, exendin‑4 shortened time to normoglycemia versus controls.

    In plain wordsIn mice, normal glucose returned sooner with exendin‑4 than without it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTime to normoglycemia
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    The time to obtain normoglycemia was shorter in the exendin-4-treated group than in controls (12 +/- 8 vs. 29 +/- 13 days, p < 0.001).
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice receiving islets, exendin‑4 lowered blood glucose at 6 weeks versus controls.

    In plain wordsIn mice, glucose was lower with exendin‑4 than in controls at 6 weeks.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose at 6 weeks
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Blood glucose at 6 weeks was 123 +/- 18 and 170 +/- 62 mg/dl in the exendin-4-treated group and controls, respectively (p = 0.008).
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice receiving islets, exendin‑4 improved glucose tolerance at 2 and 4 weeks versus controls.

    In plain wordsIn mice, exendin‑4 improved glucose tolerance more than control treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGlucose tolerance
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Additionally, the exendin-4-treated group had better glucose tolerance than controls at 2 and 4 weeks (p <0.02).
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice receiving islets, weight increased in both groups without a significant between-group difference.

    In plain wordsIn mice, weight increased similarly with and without exendin‑4.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBody weight change
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    However, both groups exhibited increased body weight over time, and weight changes did not significantly differ between the two groups throughout the study period.
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4-treated islet grafts were more prominent than control grafts.

    In plain wordsIn mice, islet grafts were more prominent with exendin‑4 than without it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGraft prominence
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Islet protection · Endocrine and hormones
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At 6 weeks after transplantation, grafts in the exendin-4-treated group were more prominent and contained more insulin-stained cells than those of controls.
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4-treated grafts contained more insulin-stained cells than control grafts.

    In plain wordsIn mice, exendin‑4 grafts contained more insulin-stained cells than control grafts.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin-stained cells
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Islet protection · Endocrine and hormones
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    At 6 weeks after transplantation, grafts in the exendin-4-treated group were more prominent and contained more insulin-stained cells than those of controls.
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 increased graft beta-cell mass versus controls.

    In plain wordsIn mice, exendin‑4 increased graft beta-cell mass compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGraft beta-cell mass
    Study

    mousen: not reported in source

    Streptozotocin-diabetic islet transplant recipients
    Comparator
    Recipients without exendin-4
    Outcome group
    Islet protection · Endocrine and hormones
    Studied dose
    Dose not stated · 6 weeksAs given in this study (mouse).

    Source sentences

    Summary
    They had 2.3-fold beta-cell mass of the graft compared with controls (0.30 +/- 0.11 vs. 0.13 +/- 0.03 mg, p = 0.012).
    1 context sentence
    Summary · context
    We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.